NantKwest (NK) : 16 days before expiry, shorts in NantKwest (NK) have reduced from 4,112,810 on Jul 29, 2016, to 3,765,576 on August 15, 2016. On an average, 237,465 shares are traded on the exchange. The outstanding bearish positions are equal to 16.4% of the float. Short sellers have covered -347,234 shares, a reduction of -8.4%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
NantKwest (NASDAQ:NK): The stock opened at $8.15 on Wednesday but the bulls could not build on the opening and the stock topped out at $8.45 for the day. The stock traded down to $7.39 during the day, due to lack of any buying support eventually closed down at $7.48 with a loss of -8.00% for the day. The stock had closed at $8.13 on the previous day. The total traded volume was 338,779 shares.
In a related news, Wilson Angela, CFO of Nantkwest, Inc., executed a transaction worth $49,987 on December 10, 2015. A total of 3,265 shares were purchased at an average price of $15.31. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
NantKwest, Inc., formerly Conkwest, Inc., is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Companys product candidates include aNK, haNK and taNK. The Companys aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus (HPV), induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16, a receptor that allows direct binding of NK cells to antibodies. The Companys taNK product candidate targets specific antigens on the surface of abnormal cells, including CD33, EGFR, HER2/neu, PDL1 and PSMA.